{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:42:02Z","timestamp":1793148122409,"version":"4.5.0"},"reference-count":34,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fili\u00e8re Muco-CFTR"},{"DOI":"10.13039\/501100006342","name":"Association Vaincre la Mucoviscidose","doi-asserted-by":"publisher","award":["RC20240503452"],"award-info":[{"award-number":["RC20240503452"]}],"id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,12,2]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Trapped gas (TG) and ventilation inhomogeneity (VI) are early markers of altered small airway function (SAF) in cystic fibrosis (CF) lung disease. The evolution of these markers in children with CF (chCF) treated with elexacaftor\u2013tezacaftor\u2013ivacaftor (ETI) remains poorly understood. Using data from multiple breath washout (MBW) and body plethysmography (pleth) from a national, real-world cohort of school-aged chCF, we tested the hypothesis that VI and TG do not consistently return to normal levels following ETI therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data from MBW and pleth tests were collected from seven centres prior to ETI initiation (month 0 (M0)), after a year of treatment (M12) and at M6 (when available). Analyses were conducted to assess the evolution of per cent predicted (pp) residual volume (ppRV), total lung capacity (ppTLC) and the ppRV\/TLC ratio, as well as the difference between pp functional residual capacity (ppFRC)\n                      <jats:sub>pleth<\/jats:sub>\n                      and ppFRC\n                      <jats:sub>MBW<\/jats:sub>\n                      as markers of TG. Global and regional VI indices were compared to those of age- and sex-matched healthy controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 192 chCF aged from 6 to 18\u2005years at ETI initiation underwent MBW at M0 and M12. Significant reductions were observed in ppRV, ppTLC, ppRV\/TLC and TG. However, 28% of the chCF cohort had ppRV\/TLC values &gt;120% at M12. MBW-derived outcomes improved significantly, but 51.9% of the cohort had lung clearance index (LCI\n                      <jats:sub>2.5<\/jats:sub>\n                      ) values at M12 that had not returned to healthy control levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ETI significantly improved SAF. However, not all outcome measures returned to normal, indicating residual lung disease in some chCF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01585-2025","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:45:20Z","timestamp":1766079920000},"page":"01585-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Persistence of lung hyperinflation and small airway dysfunction in school-aged children with cystic fibrosis treated with elexacaftor\u2013tezacaftor\u2013ivacaftor: results from the real-world MODUL-CF study"],"prefix":"10.1183","volume":"12","author":[{"given":"Lucie","family":"Colin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Delaup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Le Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Neve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Wizla-Derambure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4180-9805","authenticated-orcid":false,"given":"Iulia-Cristina","family":"Ioan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Tatopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Kieffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Blonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Plamen","family":"Bokov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Houdoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Le Clainche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Barzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Ohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Toin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5974-3269","authenticated-orcid":false,"given":"Thomas","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurianne","family":"Coutier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rola","family":"Abou Taam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Bonnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"Feghali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3576-2518","authenticated-orcid":false,"given":"Stephanie","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fayon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Letierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5537-9482","authenticated-orcid":false,"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9192-8335","authenticated-orcid":false,"given":"Philippe","family":"Reix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"2026061501450662000_12.3.01585-2025.1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026061501450662000_12.3.01585-2025.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.09.005"},{"key":"2026061501450662000_12.3.01585-2025.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.06.013"},{"key":"2026061501450662000_12.3.01585-2025.4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest computed tomography scores with elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older: the RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026061501450662000_12.3.01585-2025.5","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/ppul.26938","article-title":"Lung clearance index (LCI(2.5)) changes after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in children with cystic fibrosis aged between 6 and 11 years: the \u201creal-world\u201d differs from trial data","volume":"59","author":"Urquhart","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2026061501450662000_12.3.01585-2025.6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00004-2024"},{"key":"2026061501450662000_12.3.01585-2025.7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jcf.2022.12.012","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy in children with cystic fibrosis: a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI","volume":"22","author":"Streibel","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026061501450662000_12.3.01585-2025.8","doi-asserted-by":"crossref","first-page":"1125853","DOI":"10.3389\/fphar.2023.1125853","article-title":"Early and sustained improvements of lung clearance index from two to sixteen weeks of elexacaftor\/tezacaftor\/ivacaftor therapy in patients with cystic fibrosis: a real world study","volume":"14","author":"Appelt","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026061501450662000_12.3.01585-2025.9","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1513\/AnnalsATS.202501-103OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in 6- to 11-year-olds with cystic fibrosis","volume":"22","author":"Pittman","year":"2025","journal-title":"Ann Am Thorac Soc"},{"key":"2026061501450662000_12.3.01585-2025.10","doi-asserted-by":"crossref","first-page":"e71166","DOI":"10.1002\/ppul.71166","article-title":"Real-world improvements of lung clearance index and ventilation distribution efficiency in children with cystic fibrosis after elexacaftor\/tezacaftor\/ivacaftor initiation","volume":"60","author":"Henriksen","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"2026061501450662000_12.3.01585-2025.11","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026061501450662000_12.3.01585-2025.12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00408-024-00768-1","article-title":"Lung clearance index improves in people with cystic fibrosis not achieving a clinical important difference in forced expiratory volume in one second after elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"203","author":"Dacco","year":"2024","journal-title":"Lung"},{"key":"2026061501450662000_12.3.01585-2025.13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000543009","article-title":"The proof of the pudding is in the eating: real-life intra- and extrapulmonary impact of elexacaftor\/tezacaftor\/ivacaftor","volume":"104","author":"Vincken","year":"2025","journal-title":"Respiration"},{"key":"2026061501450662000_12.3.01585-2025.14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcf.2021.03.016","article-title":"Peripheral lung effect of elexacaftor\/tezacaftor\/ivacaftor in adult cystic fibrosis","volume":"21","author":"Stylemans","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026061501450662000_12.3.01585-2025.15","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20879"},{"key":"2026061501450662000_12.3.01585-2025.16","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201747"},{"key":"2026061501450662000_12.3.01585-2025.17","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-204023"},{"key":"2026061501450662000_12.3.01585-2025.18","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-7-138"},{"key":"2026061501450662000_12.3.01585-2025.19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.chest.2024.03.033","article-title":"Relationship between lung volumes and heterogeneity in the response to elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease","volume":"166","author":"Gramegna","year":"2024","journal-title":"Chest"},{"key":"2026061501450662000_12.3.01585-2025.20","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026061501450662000_12.3.01585-2025.21","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1002\/ppul.24863","article-title":"Limitations of regional ventilation inhomogeneity indices in children with cystic fibrosis","volume":"55","author":"Verger","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2026061501450662000_12.3.01585-2025.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00524-2024"},{"key":"2026061501450662000_12.3.01585-2025.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01519-2022"},{"key":"2026061501450662000_12.3.01585-2025.24","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ppul.24149","article-title":"Alternate gas washout indices: assessment of ventilation inhomogeneity in mild to moderate pediatric cystic fibrosis lung disease","volume":"53","author":"Nyilas","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"2026061501450662000_12.3.01585-2025.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2008.06.014"},{"key":"2026061501450662000_12.3.01585-2025.26","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1002\/ppul.27177","article-title":"Looking beyond LCI: multiple breath washout phase III slope derived indices and their application in chronic respiratory disease in children","volume":"59","author":"Riley","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2026061501450662000_12.3.01585-2025.27","doi-asserted-by":"crossref","first-page":"e71180","DOI":"10.1002\/ppul.71180","article-title":"Feasibility and utility of multiple breath washout measured Scond and Sacin in preschool children with cystic fibrosis","volume":"60","author":"Lynch","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"2026061501450662000_12.3.01585-2025.28","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21154"},{"key":"2026061501450662000_12.3.01585-2025.29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201307-1268OC"},{"key":"2026061501450662000_12.3.01585-2025.30","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00330-024-11019-5","article-title":"Artificial intelligence-driven volumetric CT outcome score in cystic fibrosis: longitudinal and multicenter validation with\/without modulators treatment","volume":"35","author":"Hadj Bouzid","year":"2025","journal-title":"Eur Radiol"},{"key":"2026061501450662000_12.3.01585-2025.31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2213-2600(25)00248-6","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study","volume":"14","author":"Sermet-Gaudelus","year":"2026","journal-title":"Lancet Respir Med"},{"key":"2026061501450662000_12.3.01585-2025.32","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00340.2024"},{"key":"2026061501450662000_12.3.01585-2025.33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ppul.26169","article-title":"Migration is not the perfect answer: how the cross-talk error correction for multiple breath nitrogen washout (MBWN2) parameters differs on directly collected vs. legacy data","volume":"58","author":"Short","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2026061501450662000_12.3.01585-2025.34","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/ppul.26430","article-title":"Reply to migration is not the perfect answer: optimized methodology to assess LCI agreement between corrected legacy multiple breath nitrogen washout data and that directly collected on updated software","volume":"58","author":"De Queiroz Andrade","year":"2023","journal-title":"Pediatr Pulmonol"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01585-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:45:17Z","timestamp":1781513117000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01585-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,15]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1183\/23120541.01585-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01585-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}